Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263

Cell Death and Disease

Volumn 6, Issue 12, 2015, Pages

  Greenberg, E F ^a,b,c   McColl, K S ^a,c   Zhong, F ^a,c   Wildey, G ^a,c   Dowlati, A ^a,c   Distelhorst, C W ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; BIRD-2 PEPTIDE; CALCIUM; CALPAIN; CASPASE; NAVITOCLAX; PEPTIDE; SULFONAMIDE;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; SMALL CELL LUNG CANCER; TUMOR CELL LINE;

ANILINE COMPOUNDS; APOPTOSIS; CALCIUM; CALPAIN; CASPASES; CELL LINE, TUMOR; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; PEPTIDES; SMALL CELL LUNG CARCINOMA; SULFONAMIDES;

EID: 85020324915     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/CDDIS.2015.355     Document Type: Article

References (49)

1. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17: 1794–1801.
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539–4544.
3. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011; 378: 1741–1755.
4. American Cancer Society. Cancer Facts and Figures, ACS, 2014.
5. William WN Jr., Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011; 8: 611–619.
6. Chan BA, Coward JI. Chemotherapy advances in small-cell lung cancer. J Thorac Dis 2013; 5(Suppl 5): S565–S578.
7. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54: 6–8.
8. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097–1099.
9. Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E et al. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 1996; 15: 31–40.
10. Lawson MH, Cummings NM, Rassl DM, Vowler SL, Wickens M, Howat WJ et al. Bcl-2 and beta1-integrin predict survival in a tissue microarray of small cell lung cancer. Br J Cancer 2010; 103: 1710–1715.
11. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014; 20: 897–903.
12. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2: 798–811.
13. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299–310.
14. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49–63.
15. Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KL, Ding H et al. Emerging understanding of Bcl-2 biology: implications for neoplastic progression and treatment. Biochim Biophys Acta 2015; 1853: 1658–1671.
16. Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther 2013; 12: 1691–1700.
17. Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 2014; 51: 219–227.
18. Vogler M. Targeting Bcl-2 proteins for the treatment of solid tumours. Adv Med 2014; 204: 1–14.
19. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681.
20. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909–916.
21. Zhu W, Cowie A, Wasfy GW, Penn LZ, Leber B, Andrews DW. Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. EMBO J 1996; 15: 4130–4141.
22. Annis MG, Yethon JA, Leber B, Andrews DW. There is more to life and death than mitochondria: Bcl-2 proteins at the endoplasmic reticulum. Biochim Biophys Acta 2004; 1644: 115–123.
23. Thomenius MJ, Wang NS, Reineks EZ, Wang Z, Distelhorst CW. Bcl-2 on the endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins. J Biol Chem 2003; 278: 6243–6250.
24. Chen R, Valencia I, Zhong F, McColl KS, Roderick HL, Bootman MD et al. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER. J Cell Biol 2004; 166: 193–203.
25. 2+ uptake by mitochondria without affecting ER calcium store content. Cell Calcium 2008; 44: 324–338.
26. Chang MJ, Zhong F, Lavik AR, Parys JB, Berridge MJ, Distelhorst CW. Feedback regulation mediated by Bcl-2 and DARPP-32 regulates inositol 1,4,5-trisphosphate receptor phos-phorylation and promotes cell survival. Proc Natl Acad Sci USA 2014; 111: 1186–1191.
27. Rong Y, Bultynck G, Aromolaran AS, Zhong F, Parys JB, De Smedt H et al. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc Natl Acad Sci USA 2009; 106: 14397–14402.
28. Rong Y, Aromolaran AS, Bultynck G, Zhong F, Li X, McColl KS et al. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol Cell 2008; 31: 255–265.
29. 3 receptor interaction. Blood 2011; 117: 2924–2934.
30. 3 receptor. PLoS One 2013; 8: e73386.
31. Lavik AR, Zhong F, Chang MJ, Greenberg E, Choudhary Y, Smith MR et al. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. Oncotarget 2015; 6: 27388–27402.
32. 3R-derived peptide targeting the BH4 domain of Bcl-2. Cell Death Dis 2013; 4: e632.
33. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421–3428.
34. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440–446.
35. Monaco G, Decrock E, Akl H, Ponsaerts R, Vervliet T, Luyten T et al. Selective regulation of IP(3)-receptor-mediated Ca(2+) signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl. Cell Death Differ 2012; 19: 295–309.
36. Zhivotovsky B, Orrenius S. Calcium and cell death mechanisms: a perspective from the cell death community. Cell Calcium 2011; 50: 211–221.
37. Norberg E, Karlsson M, Korenovska O, Szydlowski S, Silberberg G, Uhlen P et al. Critical role for hyperpolarization-activated cyclic nucleotide-gated channel 2 in the AIF-mediated apoptosis. EMBO J 2010; 29: 3869–3878.
38. Low KE, Karunan Partha S, Davies PL, Campbell RL. Allosteric inhibitors of calpains: reevaluating inhibition by PD150606 and LSEAL. Biochim Biophys Acta 2014; 1840: 3367–3373.
39. 2+ signals according to the strength of T cell receptor activation. J Cell Biol 2006; 172: 127–137.
40. Vanags DM, Porn-Ares MI, Coppola S, Burgess DH, Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J Biol Chem 1996; 271: 31075–31085.
41. Jahchan NS, Ouyang G, Luo K. Expression profiles of SnoN in normal and cancerous human tissues support its tumor suppressor role in human cancer. PLoS One 2013; 8: e55794.
42. 2+ for cancer cell proliferation and survival. Nat Rev Cancer 2008; 8: 361–365.
43. 3 receptors. Biochim Biophys Acta 2013; 1835: 180–193.
44. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today 2015; 20: 122–128.
45. Miller MJ, Foy KC, Kaumaya PT. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 2013; 15: 166–176.
46. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305: 1466–1470.
47. LaBelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest 2012; 122: 2018–2031.
48. Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G et al. Small-molecule Bcl2 BH4 antagonist for lung cancer therapy. Cancer Cell 2015; 27: 852–863.
49. Artymovich K, Appledorn DM. A multiplexed method for kinetic measurements of apoptosis and proliferation using live-content imaging. Methods Mol Biol 2015; 1219: 35–42.